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Abstract
The process of developing and testing drug candidates is a slow and costly en-
deavor. The mainstream technologies such as bulk 2D cell culture techniques have
been proven insufficient to capture the pharmacokinetics and pharmacodynamics of
drug compounds in humans. Animal models, despite their central role in drug devel-
opment studies, fall short to predict the human-specific mechanisms of drug clear-
ance and toxicity. In this thesis project, I have designed and evaluated application-
specific single-cell and organ-on-a-chip microfluidic platforms for drug and chemical
compound testing applications. The fundamental advantage offered by single-cell
analysis, is the possibility of capturing the behavior of individual cells which, reveals
valuable information on the heterogeneity in a cell population. Simultaneously, cre-
ating human-based physiologically relevant organ-mimetic microenvironments for
drug metabolism and toxicity is becoming increasingly critical. My thesis work, by
taking advantage of experimental approaches, qualitatively and quantitatively vali-
dates solutions to address the aforementioned challenges in producing relevant data
on drug metabolism and toxicity.
A single-cell analysis platform built with the combination of a 4-inlet microfluidic
device, a single-beam optical tweezers setup and an epi-fluorescence microscopy stage
was used to study the co-administration of the trivalent form of arsenic, As (III), with
a Hog1 inhibitor in yeast. In this work we showed that uptake of sodium arsenite
could be regulated in single cells. In the next step, I developed a microfluidic device
to facilitate high throughput single-cell studies. The device offered the possibility
of studying hundreds of cells in each experiment run. Additionally, diffusion-based
flow profiles could be administered in this device thanks to the miniature geometry
of the microchannels. To promote the formation of 3D tissue-like structures in a
physiologically relevant environment, I tailored a microfluidic device to mimic the
geometrical hexagonal structure of a classic liver lobule. In this work I showed
that human liver cells could be maintained functional in the microfluidic devices for
short-term as well as long-term culture periods.
Keywords: Microfluidics, laminar flow, optical tweezers, fluorescence microscopy, single-
cell analysis, heterogeneity, Saccharomyces cerevisiae, yeast cells, organ-on-a-chip, liver,
liver-on-a-chip, HepG2, hiPSC, hiPSC-derived hepatocytes, drug metabolism, drug toxic-
ity
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Chapter 1
Introduction
T he ultimate goal of biology and medicine has chiefly been to improve the quality ofhuman life. Through elemental and experiential expansion of knowledge, the disci-
pline has successfully prevented or remarkably alleviated the inherited and environmental
risks on the lives of humans. During the course of history, development of human soci-
eties has faced drastic challenges imposed by the outbreak of epidemics, and emergence
of unknown diseases. To cope and actively respond to such threats, understanding the
working principles of living organisms has been an unceasing commitment for the scientific
community. Exploring these mechanisms has been vital to develop effective treatments to
eliminate viral or bacterial infections and battle diseases with a challenging genetic nature
such as cancer.
The process of drug development however, has been potentially hampered by the
drawbacks of currently dominant screening approaches such as two-dimensional (2D) cell
culture and animal studies. Traditional cell culture methods, where cells are cultivated on
flat surfaces have not experienced considerable changes since their introduction in 1912
by Alexis Carrel [1].
These techniques have proven useful in providing high throughput and reproducible
information on early-stage screening studies. However, they offer limited capabilities to
control the cellular environment, lack the possibility to create cell-specific physiological
niche, fail to systematically study and analyze individual cells or achieve and capture
spatiotemporal dynamics [2].
More importantly, the complex absorption, distribution, metabolism, excretion and
toxicity (ADMET) mechanisms of drug compounds in vivo are unattainable in these sys-
tems. Animal studies are an indispensable screening tool in the process of drug develop-
ment. However, in addition to the ethical concerns associated with animal trials, they have
proven to be an insufficient predictive model for conclusive decision making on humans,
due to fundamental inter-species genetic variations [3, 4]. Moreover, the many emerging
legislations and guidelines regarding animal care and wellbeing in biomedical research,
is going to alter the way drug development and toxicity experiments are currently man-
aged. Consequently, overcoming these limitations calls for establishing novel predictive
and reliable in vitro model systems.
Early-stage studies for new drug development has benefited from the integration of
systems biology [5–7] tools and in silico studies. Mathematical computation in combina-
tion with measured gene expression, proteomics and metabolomics data has been applied
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to model the dynamics of biological systems. Currently, due to the complex interactions
in biological systems, these approaches are more relevant in cases of simpler organisms
and specific signaling pathways. The promising outlook of systems biology research to
enhance the process of drug development must be complemented with strong experimen-
tal biological knowledge on the cellular as well as tissue level behavior. This will provide
relevant information for modeling the cell, physiology of organs and the diseases [8]. The
emergence of interdisciplinary approaches such as single-cell analysis and organ-on-a-chip
technology can be perceived in this regard.
1.1 Single-cell analysis versus population-level stud-
ies
The stochastic nature of gene expression is known to be one of the major sources of
cell-cell variations in isogenic populations [9, 10]. The intrinsic noise originates from the
inherent stochasticity associated with chemical reactions on the molecular level in a cell.
In addition extrinsic noise arising from other sources of fluctuations in cellular dynamics,
eg. regulatory factors, gives rise to heterogeneous gene expression levels in a cell popu-
lation [11]. Such variability in the amount of protein production in different cells by a
certain gene is referred to as genetic or transcriptional noise and can lead to subpopulations
with dissimilar phenotypes and significant variations in cell development, metabolism, cell
cycle, aging and stress responses [12]. Nevertheless, it is clear that an average read out
of a cell population is not necessarily the true representative of the cellular behavior of
that population but merely a broad picture that can miss important outliers [13]. In
diseases like cancer where intra-tumor heterogeneities inflict challenges on effective drug
development, understanding the dynamics on the single-cell level aids better characteri-
zation of such complexities [14, 15]. To address the need for high throughput, easy and
accurate cell sorting in heterogeneous cell populations, methods such as flow cytometry
or fluorescent-activated cell sorting (FACS) have been developed [16,17]. Other molecular
analysis technologies such as fluorescent in situ-hybridization (FISH) [18, 19] and patch
clamping [20–22] have also been used on the single-cell level to better understand the
cell-cell variability.
Compared to the benefits offered by these prevalent techniques, development of special-
ized microfluidic devices for single-cell purposes has shown prominent advantages. These
devices present the potential to collect single-cell data and monitor real-time cellular be-
havior with high spatiotemporal resolutions. Introduction of microfluidics and lab-on-a-
chip (LOC) or micro total analysis systems (µTAS) [23–27], has created opportunities
for unprecedented achievements in chemical and biological sample handling, otherwise
impossible by means of mainstream technology.
Under a precisely controllable environment, single-cell microfluidics have facilitated
minimized diffusion length scales due to high surface-to-volume ratios [28], minute con-
sumption of rare chemicals and ultimately high throughput data acquisition possibili-
ties [29–32]. In addition, single-cell microfluidics have been successfully combined with
other cell manipulation approaches such as optical tweezers, acoustic waves [33], magnetic
cell sorting [34], dielectrophoresis [35] and integration of micropumps and microvalves
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[36–38]. In collaboration with amplification technologies such as polymerase chain reac-
tion (PCR) [39,40] these platforms have paved the way to acquire large-scale detailed data
with strong statistical value. This data has been used to build databases and predictive
biological models [41].
1.2 Organ-on-a-chip microfluidic platforms
In light of recent advances and development of customizable microfabricated cell handling
devices, the novel category of organ-on-a-chip (OOC) has emerged. The appearance of
this class of perfusion devices originates from the pressing need for accurate and human-
based predictive screening systems throughout the entire drug development procedure [42].
2D monolayer cultures do not represent the close physiological conditions of the target
organs due to the changes in enzymatic expression and altered cell-cell interactions [43,44].
Moreover, in static cultures dynamics of drug metabolism and clearance are overlooked.
For instance, it has been shown that much higher concentrations of drugs are required in
2D cultures to induce comparable efficacy and toxicity responses compared to perfusion
models [45].
The initiative towards addressing the lack of predictive human-based in vitro tools
involves variety of recent advances in developing 3D organoid models [46], spheroid cultures
[47, 48], 2D co-culture drug screening plates [49], 3D tissue-like perfusion systems [50–53]
and multi-organ-mimicking structures [54]. The effect of the flow condition has been
shown previously [45,55] to enhance cell viability and functionality by constant cell waste
removal from the culture environment and fresh media replacement. Moreover, introducing
xenobiotics under controlled dynamic flow rates promotes reproduction of in vivo-like
conditions.
The outstanding prospective of OOC however, is in fact the compatibility of these
systems with development of personalized medicine. Incorporating patient-specific human
cells in long-term perfusion microfluidic devices and screening for available therapeutics,
based on each patient’s genetic background, could provide a roadmap to create personal-
ized treatment procedures. As a result, this could also empower approaches to effectively
battle cancer, genetic and neurodegenerative diseases.
The main goal of my thesis work has been to develop customized microfluidics and
qualitatively as well as quantitatively assess experimental approaches to screen test drugs
and chemical compounds in a physiologically relevant dynamic microenvironmet. This
work is formulated around addressing these three specific aims:
Aim 1:
The first aim was to assess how the regulation of sodium arsenite, as a major sub-
stance in chemotherapeutics as well as an environmental pollutant, could be controlled in
a dynamic microenvironment.
Aim 2:
The second aim was to transform the microfluidic chamber to a more versatile design
to increase the throughput of the studies, while maintaining the advantages offered by
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single-cell analysis.
Aim 3:
The third aim was to adapt and tailor the microfluidic platform to a physiologically rel-
evant environment to facilitate long-term culture and maintenance of adherent mammalian
cells as well as promote human-based in vitro devices for drug screening applications.
Aim 1 was investigated in paper I. We used a custom-made 4-inlet microfluidic de-
vice in combination with optical trapping for cell handling. As a whole eukaryotic model
organism, Saccharomyces cerevisiae, yeast, was used for the studies. We investigated the
regulation of As (III) uptake in yeast cells by co-administration of a Hog1 inhibitor com-
pound.
Aim 2 was investigated in papers II and III. To address the limitations of cell han-
dling by optical tweezers, a hydrodynamic microfluidic device to capture single yeast and
mammalian cells was designed and fabricated. Cell seeding procedure was made signif-
icantly easier compared to our previous technique and features such as sheath flow and
possibility of diffusion-based mass transport were introduced to the device.
Aim 3 was investigated in paper IV. In this paper we mimicked the convection-
diffusion mass transport in the structure of a classic liver lobule for long-term maintenance
of hepatocytes. The cell culture chambers were arranged in a honeycomb configuration
and human cell-lines were used to characterize the device.
Chapter 2
Cell handling
I
n this chapter principles of fluid mechanics in microfluidics in the scope of this thesis
work have been described briefly. Working principles of optical tweezers as a powerful
tool to handle biological samples have been explained.
2.1 Microfluidics
The very early microfluidic devices fabricated with the use of modern microtechnology,
date back to 1960s to the ink jet printer nozzles developed in IBM and the research
on chromatography conducted in Stanford University [56]. Since then the microfluidics
field and the innovative use of different materials in fabrication of microfluidic devices
have substantially expanded. Early-on fabrication techniques which, primarily employed
silicon and glass, have evolved to widespread polymer-and plastic-based devices [57]. Poly-
(dimethylsiloxane), PDMS, has been the dominant material for microfluidic experimental
prototyping. Unique features of PDMS, including sub-micron feature size yield, gas per-
meability, optical transparency and the ability of making active fluidic components have
made this polymer a desirable choice for researchers in the life sciences [58].
To date, a vast variety of microfluidic systems with different applications have emerged.
Highly controlled single-cell analysis systems [29, 59] to investigate genotypic and phe-
notypic heterogeneities in cells, have made high throughput and parallelized single-cell
culture, imaging and data acquisition possible. On chip cell lysis and protein, DNA and
RNA isolation using an integrated network of microfluidic valves have been reported.
Droplet-based microfluidics taking advantage of colloidal fluidics have demonstrated
promising applications in cell sorting, single-cell analysis, single-cell sequencing and single-
cell omics [60].
Digital microfluidics, have emerged as a new approach to manipulate nanoliter-droplets
on the surface of arrays of electrodes. A complete cycle of culturing mammalian cells
followed by on-chip reagent handling has been demonstrated [61].
Blood plasma separation devices in conjunction with tailored surface chemistry have
given rise to point-of-care [62–64] platforms that can be operated without the need for
bulky laboratory equipment.
Paper- [62, 64, 65] and plastic [66, 67] microfluidic devices easily fabricated by laser
cutting, 3D printing or hot embossing, are on the way to transform healthcare specifically
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in low-resource areas such as developing countries and military camps.
Advances in precision fabrication of microfluidic platforms has given rise to a new
generation of tools to mimic the physiological environment of cells and eventually re-
produce the functionality of specific cell types or whole organs on chip. OOC plat-
forms [50–54, 68–70] are considered amongst the promising technologies for drug testing
and the future of personalized medicine.
2.1.1 Fluid dynamics in micron-scale structures
Basic fluid dynamic principles describe the behavior of the flow inside the microfluidic
devices. The dominant fluidic regime in micron and sub-micron scales is normally the
laminar flow [71]. In contrast to the turbulent and unpredictable streams in macro systems,
laminar flow moves in parallel and predictable trajectories and in channels with rigid
boundaries forms a parabolic profile as shown in figure 2.1(A).
The dominance of capillary and viscose forces in microfluidics, enables the predictable
manipulation of fluids to handle biological samples [72], unlike the macro-scale regime
where inertial forces significantly dominate. At small scales several approaches have been
followed to analyze the flow behavior based on conservation of mass, momentum and en-
ergy. Details of such analysis approaches have been discussed in various fluid mechanics
books [73–75]. In the context of this work, the focus has been on the behavior of incom-
pressible, Newtonian and isotropic fluids where the density of the fluid is independent
of the pressure and the viscosity is independent of the flow velocity. Governed by the
Navier-Stokes equation, the relation between inertial and viscous forces under the velocity
(u) and the pressure (p) can be shown as
ρ
(δu
δt
+ u.∇u
)
= −∇p+ η∇2u+ f. (2.1)
Based on the characteristics of the fluid, density (ρ) and dynamic viscosity (η), eq.
2.1 determines the velocity of the fluid at a certain time and position. In this equation, f,
denotes the body forces such as gravity [75].
Under the certain conditions when we consider the fluid flow to be laminar, the inertial
term ρ
(
δu
δt + u.∇u
)
in the Navier-Stokes equation can be neglected. Therefore, with the
body forces negligible compared to viscous forces, the behavior of the flow is described by
the Stokes equation
−∇p = η∇2u. (2.2)
Stokes equation has been the basis of velocity field simulations in papers I-IV. For
design purposes however, a convenient and practical way to determine the geometrical
aspects of the microchannels is to use the dimensionless ratio between the inertial and
viscous forces, the Reynolds number, [76] specified by eq. 2.3
Re =
ρu0L
η
. (2.3)
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Figure 2.1: Demonstration of the flow in laminar (A) and turbulent (B)
regimes. In the laminar flow regime trajectories of the flow form a parabolic
shape with the maximum flow velocity in the center of the channels. The tur-
bulent flow profile shows formation of flow eddies and unpredictable behavior
along the channels.
In eq. 2.3, u0 and L are the characteristic velocity and length scale in the microfluidic
channel. To calculate the Reynolds number for the microchannels with a rectangular cross
section, the length scale L can be approximated by the hydraulic diameter, Dh, [76] of the
channels given by eq. 2.4, where a and b are the dimensions of the microchannel.
Dh =
4ab
2(a+ b)
(2.4)
One can argue that for small Reynolds numbers, typically (Re  1), the laminar
flow conditions are satisfied, as opposed to the large Reynolds numbers (Re > 2300) in
the turbulent flow conditions. In the devices presented in papers I-IV the Reynolds
numbers were below 0.1.
In the laminar flow regime, small spherical particles, are subjected to Stokes drag
forces, also known as hydrodynamic forces. For a particle with the radius of r0 under the
relative velocity of U the drag force can be defined as
FD = −6piηr0U. (2.5)
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In papers II and III, hydrodynamic forces (in the oder of pN) have been exploited
for trapping and immobilizing cells.
Perhaps the most important property in the micron-scale regime is that mixing of
chemical species is dominated by diffusion of the particles rather than convection forces.
The diffusion coefficient (D) for different particles has an inverse relation to the radius
of the particles and changes in a temperature-dependent manner. This relation can be
described by
D =
kT
6piηr0
. (2.6)
In this equation k is the Boltzmann constant, T is the temperature and r0 is the radius
of the particles. Based on the Fick’s law of diffusion, the flux of particles, J, from a higher
to a lower concentration of c with a diffusion coefficient of D, is explained as
J = −D∇c. (2.7)
In the micron-scale geometry of the microfluidic channels, under the assumption of
time-independent D, with combination of the convective term (cu) and the Fick’s diffusion
law in the continuity equation, the convection-diffusion equation can be simplified to
∂c
∂t
= D∇2c− u · ∇c. (2.8)
This principle has been considered in the numerical simulations for the diffusion of
substance in relation with the velocity field inside the microfluidic devices in papers I-IV.
For the design purposes of the microchannels in regard to convection and diffusion,
following a similar approach to the Reynolds number, the Pe´clet number has been used.
The Pe´clet number is a dimensionless value, which denotes the ratio between the
convective and diffusive mass transport in a fluidic system. This relation is described in
eq. 2.9
Pe =
uDh
D
. (2.9)
For low Pe´clet numbers (Pe  1), the time required for transport of particles by
diffusion is shorter than the time required for advection, whereas in larger Pe´clet numbers
(Pe 1), transport of particles is advection dominated. The measure in contrary to the
Reynolds number does not have a typical indicative range for microfluidic devices and can
vary based on the required channel geometries and designated applications.
2.2 Optical tweezers
The simple working principles of optical trapping has offered promising advantages in the
nanometer to hundreds of microns length scales [77]. Multi-particle trapping, complex 3D
holographic field generation, measurement of small interaction forces and active cell sorting
are perhaps the areas that optical trapping has received the most profound enthusiasm and
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development in the recent years [78]. Optical tweezers in handling biological objects [79,80]
has been used widely as a non-invasive manipulation technique.
This includes applications such as systematic cell positioning inside microchambers
[81–83], mechanical cell deformation and membrane elasticity measurements [84–86], mem-
brane tether extraction [87], cell fusion experiments [88], in vivo manipulation of red
blood cells [89], biochemical and mechanical induction of signaling events in mammalian
cells [90, 91], measurement of live cell-mediated mechanical forces [92], to name a few.
2.2.1 Working principles of optical tweezers
The basic principle behind optical tweezers is that light carries momentum in addition to
energy and through transfer of this momentum, forces can be applied to objects. This
phenomenon was demonstrated experimentally by Ashkin et al for dielectric particles
in 1986 [93]. Based on the dimensions of the interacting object different theories are
used to explain the momentum transfer and optical forces. For instance in case of small
spherical particles with a radius of r0 where r0  λ (λ is the wavelength of the incident
light), Rayleigh scattering is used and when r0  λ ray optics regime applies in the
approximations [94].
In cases where the dimensions of the particle are in the order of the light wavelength,
the theories used to explain the two former conditions have proven insufficient to calculate
the optical forces. Therefore, a generalized Lorentz-Mie scattering in a Gaussian beam [95]
or applying a dipole approximation on any sizes of dielectric particles in a focused laser
light have been proposed [96]. Figure 2.2 shows an example where the size of the particle
r0 is larger than λ. The particle is attracted to the center of the focus of the beam and
settles below the beam waist. The effect of reflection of the laser on the surface of the
particle has been neglected in this figure.
To trap micron-scale particles e.g. living cells, a strongly focused laser beam, typically
through a microscope objective with high numerical aperture (NA) provides the sufficient
light intensity. The direction of the forces exerted on the particle is always in the opposite
direction of the particle displacement. Therefore, the gradient forces are referred to as
restoring forces that maintain the particle close to the center of the focus under the
equilibrium conditions.
The exerted force on the cells is calculated through the Hooke’s law
F = −k∆x. (2.10)
As seen in eq. 2.10, the optical forces typically in the order of fN to hundreds of pN
are negatively proportional to the displacement of the particle (∆x) with a constant k
referred to as the trap stiffness.
A particularly important detail to account for when using optical tweezers in live-cell
handling is to minimize the risks of photo-damaging and heat generation due to absorp-
tion. Therefore the infrared and far-infrared wavelengths are chosen due to relatively low
absorption in the cells. Additionally, low optical powers (in mW range) typically required
for optical trapping systems serve this purpose adequately. In our experiments in paper
I, we used optical tweezers to create customizable arrays of cells placed in controlled dis-
tances in respect to each other. This, primarily was to assure that cell-cell interactions did
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Figure 2.2: For particles in the close proximity of a highly focused laser beam
a gradient force towards the center of the focus attracts the particles to the
trap (A). The amount of forces exerted on the trapped particle are equal
and opposite to the direction of the radiation pressure from the momentum
transfer to the particle. The total force applied to the particle is F and is the
combination of Fα and Fβ (B). Fα and Fβ are the gradient forces of the incident
rays α and β respectively.
not influence the single-cell behavior to the environmental changes and that the individual
cell responses were recorded. Combination of optical tweezers with a 4-inlet microfluidic
chamber and fluorescence microscopy was used in paper I to conduct real-time single-cell
experiments.
Chapter 3
Cell imaging
3.1 Brightfield and fluorescence microscopy
F luorescence microscopy is amongst the most popular and widespread tools used inmodern biological studies. The combination of light microscopy with fluorophores [97]
has revolutionized the fundamental approaches made towards resolving the details of sub-
millimeter and sub-micron organisms. In a light microscope setup including an objective
and an ocular a magnified image of the samples can be produced and captured by means
of photosensitive detectors or optical cameras [98]. Despite the emergence of label-free
detection techniques such as mass spectroscopy (MS) [99], quartz crystal microbalance
(QCM) [100] or surface plasmon resonance (SPR) [101], fluorescence microscopy techniques
have persisted as a key approach to visualize and acquire data on the dynamics of cellular
and molecular systems [102]. The possibility of fusing proteins of interest with fluorescent
proteins e.g. green fluorescent protein (GFP) [103] has provided the scientists with an
exceptional tool to trace and record the protein up-regulation, misfolding, degradation
and interactions in living cells in real time.
GFP and its counterparts have a fairly simple working principle which relies on ex-
citation and relaxation of photons at different wavelengths. Based on the Jablonski dia-
gram [104] depicted in figure 3.1, the fluorophore molecule or any particular fluorescent
protein has to be brought up to the excitation state by the incident photons of energy
hν1 where ν is the photon frequency. After excitation of the ground state electrons to a
higher energy level, a photon of lower energy hν2 (ν2<ν1) is emitted upon relaxation of
the excited electrons. The emission photons can then be detected apart from the incident
photons due to the wavelength differences [102].
In a regular setup of an epi-fluorescent microscope as seen in figure 3.2, a broad-
band excitation light source is used to illuminate the sample. To increase the angle of
light collection and therefore the amount of collected light in the objective, a high NA
objective is used. Equation 3.1 shows the relation between the NA, refractive index of
the surrounding medium (n) and (θ), the half angle of the cone of light collected by the
objective.
NA = nsinθ (3.1)
An immersion medium such as water or oil with a higher refractive index compared to
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Figure 3.1: Illustration of fluorescence in a Jablonski diagram. The electrons
of the ground state (S0) in the fluorophore become excited upon receiving
energy from the excitation light with the energy of hν1. After relaxation from
the excited states (S1 and S2) to the ground state via internal conversion, the
electrons emit a photon of lower energy hν2 and longer wavelength.
the specimen is used together with the high NA objective to allow for the maximum light
collection angle. In the epi-fluorescent microscope, the emission light from the sample is
collected through the same illumination objective. The incident light is filtered out through
the emission filters and only the red-shifted wavelength from the fluorescent molecules is
detected [97].
3.1.1 Confocal fluorescence microscopy
Unlike the epi-fluorescence microscopy where the entire field of view is illuminated by a
broad band lamp, in confocal microscopy a laser beam with a specific wavelength is fo-
cused by a high NA objective to excite the sample. Since the laser beam is focused on a
single spot on the specimen, the sample needs to be scanned in order to create an image.
Therefore instead of an optical camera a photodetector or otherwise called a photomul-
tiplier tube is used for signal detection. The emission signal from each illuminated point
is collected and stored in a computer. This data is then used to reconstruct the image.
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Figure 3.2: In an epi-fluorescent microscope setup the sample (1) is illumi-
nated through the objective (2). Components such as dichroic mirror (3) and
the filter cube (4) which, contains the excitation and emission filters for the
designated illumination wavelengths are located In the optical path. The halo-
gen lamp (5) is usually a broad-band light source, used to excite the sample.
Through the filter cube, the fluorescent signal from the samples passes the
tube lens and the blocking filter (6) and is detected by means of a detection
device e.g. an EMCCD camera (7). (8) shows a close-up view of the excitation
and emission in the sample plane.
For collection of the emission signal from the sample, confocal imaging takes advantage
of a fairly simple principle. When the multiple points along the depth of the sample are
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excited, the emission signal from the points that are out of focus are blocked by a pin-
hole placed at a conjugate plane to the sample plane. This way, only a small fraction of
the emission light from the out-of-focus points reaches the detector and a high contrast
is achieved in the final image. To image the whole depth of the sample the objective is
refocused on multiple sections with defined splitting distances. By constructing the image
out of each scanned optical section, a 3D image can be reconstructed. More details on
biological confocal microscopy can be found at [105].
In the scope of this work brightfield, epi-fluorescence and confocal microscopy have
been used to visualize protein aggregates (papers I and III) and for live cell staining
image acquisition.
Chapter 4
Biological model systems
T his chapter describes the biological systems that have been studied in this thesis.Saccharomyces cerevisiae or yeast cells have been chosen for the experiments in pa-
pers I-III. The availability, ease of cultures and preparation, flexibility and access to a
large variety of strains are the advantages offered by yeast. In our experimental settings,
yeast cells were exposed to extracellular stimuli in two different microfluidic chambers and
cellular responses were recorded by time-lapse imaging.
To promote physiologically relevant human-based in vitro models to study efficacy
and cytotoxicity of drug candidates, we used human liver cells. Human hepato-cellular
carcinoma cell-line (HepG2) and human induced pluripotent stem cell (hiPSC)-derived
hepatocytes were cultured in the microfluidic devices.
4.1 Saccharomyces cerevisiae
Saccharomyces cerevisiae also known as brewers or bakers yeast has a historical role in
various developmental phases of the ancient and modern human society. Yeast has long
been used to make bread, beer and wine, yet one of the most important contributions of this
eukaryotic organism has been in the advancement of knowledge in the life sciences [106].
Yeast cells have unique properties similar to higher eukaryotic organisms including cell
components such as nucleus and mitochondria as well as the cell cycle, DNA replication
and interacellular signaling.
A disruptive development has occurred in eukaryotic biology after the sequenced
genome of yeast was published for the first time in 1996 [107]. This breakthrough pro-
vided the opportunity to genetically modify and study the biology of different strains,
explore the underlying mechanisms of signaling pathways, discover relations between the
gene expression and protein functions in the cell and introduction of completely new fields
of research such as ”systems biology” and ”functional genomics” [108,109].
Additionally, the comparison between the yeast and human genome revealed that most
of the gene and protein functions were conserved in yeast. Homologues of many of the
genes involved in the diseases in humans have been found in yeast. It has also been shown
that a recognizable percentage (47%) of genes in yeast have human orthologs and can be
replaced by the human genes [110]. Therefore, yeast has presented itself as an easy-to-
use experimental system where a majority of molecular mechanisms involved in human
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diseases such as cancer and aging could be studied.
A single yeast cell represents a complete eukaryotic organism which, makes it a desir-
able model for studies targeting certain diseases such as Alzheimer’s [111, 112], Hunting-
ton’s [113–115] and Parkinson’s as well as investigating the factors involved in apoptosis
and the process of aging [116–118]. Figure 4.1 shows a microscope image of budding yeast
cells. Yeast cells are typically grown in media rich in glucose and amino acids. Yeast ni-
trogen base (YNB) is typically the choice when culturing yeast for fluorescent microscopy
purposes due to the low auto-fluorescence of this medium. YNB is supplemented with
glucose and amino acids. Yeast cells divide in a process referred to as budding. Each
cell produces fresh buds or daughter cells that eventually grow to adult cells and undergo
the growth cycle. In the logarithmic growth phase, yeast cells divide at their maximum
rate until due to the consumption of the nutrients in the growth media, cells enter the
stationary phase and the growth rate plateaus.
Many of the signaling pathways are conserved in yeast, and this is one of the most
interesting properties that can be used for studying the mechanisms of cellular behavior in
humans. Signaling pathways are often described as a cascade of protein interactions and
explain how cellular responses are mediated. For instance, in the high osmolarity glycerol
(HOG) pathway [119] in yeast, the two membrane receptors referred to as Sln1 and Sho1
are activated in response of the cell to the external stress and osmotic changes. The HOG
pathway belongs to a large family of signaling pathways called mitogen activated protein
(MAP) kinase. In the HOG MAPK pathway, when the osmolarity of the environment
increases, a series of kinases activate their downstream components. Specifically, MAPK
Hog1 protein is activated through phosphorylation and migrates to the cell nucleus [120].
Hog1 accumulation in the nucleus results in specific gene expression which increase the
glycerol level in the cell [121] and adapts the intracellular osmolarity to the new osmotic
conditions.
In my thesis I have used a small molecule MAPK Hog1 inhibitor compound [122]
that impairs the activity of this protein and potentially results in the increase of external
sodium arsenite uptake by yeast cells (paper I).
4.2 Human liver
4.2.1 Physiology of the liver
The liver is the largest inner organ of the body. The liver has the important role of
metabolism and detoxification of the compounds entering the vasculature system of the
body, including nutrients and xenobiotics. The liver consists of parenchymal (PC) and
non-parenchymal cells (NPC). Hepatocytes, the PC part of liver, comprise around 60% of
the cells in the organ. Hepatocytes have a polygonal appearance and show at least one or
two prominently round nuclei. These cells are key to the exocrine and endocrine functions
of the liver. Hepatocytes exhibit cell polarity and form distinct luminal domains restricted
by the tight junctions between the adjacent cells. This polarized organization, results in
formation of narrow channels of bile canaliculi. Hepatocytes exert bile into the canaliculi
network which, through the bile ducts flows to the gallbladder, the common bile duct
and the intestine [123]. Expression of the liver-specific protein albumin and phase I and
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Figure 4.1: Brightfield microscope image of budding yeast cells. Magnification
of the objective = 100 ×. Scale = 5 µm.
phase II metabolism of drugs are other important functions of the liver hepatocytes [124].
The non-parenchymal part of liver includes multiple cell types such as liver sinusoidal
endothelial cells (LSEC), Kuffer cells (KC) and stellate cells (SC). Each of these cell
types has specialized duties [125]. Hexagonal classic liver lobules incorporate the liver
vasculature system. The portal triads including the hepatic artery, hepatic portal vein and
the bile ducts extend through the hepatic cords and via the sinusoid structures maintain
the continuos exchange of oxygenated blood, hormones, vitamins and liver enzymes within
the tissue [126]. The hepatic cords extend in a radial fashion towards the center of each
lobule where a branch of central vein is located. The processed molecules including cell
waste and drug metabolites drain out through the central vein to the hepatic vein and join
the blood circulation in the inferior vena cava [126]. Endothelial cells comprise the majority
of the NPCs in the liver. The lining layer of cells around the liver sinusoidal cords and
extending from the portal triads are the LSECs. These cells exhibit a unique fenestrated
membrane structure and are responsible to shield the hepatocytes from the shear-imposed
stress of the blood flow while allowing the diffusion of vitamins, hormones, drugs and
nutrients from the blood capillaries [127, 126]. Apart from having the role of barriers
between the blood flow and the PC, these cells have unique scavenger properties which
involves them in the uptake of antigens, elimination of endotoxins, activating leukocytes
by secreting cytokines and chemokines and regulating the inflammatory response of the
liver [128]. The KCs are the tissue macrophage cells present in the liver. KCs have been
studied for their central role in the hepatic responses to toxicity and acute or chronic
liver tissue damages. These cells are known to be responsible for secretion of cytokines
such as tumor necrosis factor α (TNFα) and release of reactive oxygen species (ROS) in
response to liver damage and contributing to activation of apoptosis in hepatocytes. On
the contrary, there are recent reports that KCs are not only respondents and mediators of
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the liver toxicity and injury but, they can also assume a protective function in the anti-
inflammatory responses of the liver [129]. SCs reside in the space between the PCs and
the LSECs known as the space of Disse´. SCs are known to have the major contribution
in collagen production and creating extra-cellular matrix (ECM) in case of chronic liver
injury which, promotes the liver regeneration and alleviates the damage. These cells are
also the major source of vitamin A storage in the body. There is also evidence that SCs
are actively involved in the chronic liver inflammatory response by secreting inflammatory
cytokines to modulate the liver injury. Secretion of transforming growth factor β (TGF-β)
and connective tissue growth factor (CTGF) upon activation and increased levels of ECM
expression by SCs in chronic damage can lead to liver fibrosis [130].
4.2.2 Primary human hepatocytes and alternative liver cell-
line models
Early-stage drug efficacy and toxicity predictions is a pressing demands due to the signif-
icant impact of drug-induced liver injury (DILI) on the process of developing new drug
candidates. The high failure rates in animal studies, clinical trial phases or even after the
drug approval are some of the challenges standing in the way of getting treatments to the
patients in need [131].
Primary human hepatocytes (PHH) are the gold standard, a well established biological
model system, to study metabolism of endogenous and exogenous compounds, detoxifica-
tion and clearance of drugs, mechanisms of protein synthesis and enzyme regulations [132].
Freshly isolated or cryopreserved primary hepatocytes are widely used as in vitro sources
for drug metabolism, co-administration and drug-drug interactions [133]. The serious lim-
itations with PHH are, however, the shortage of high-quality cell lots and a significant
lot-to-lot variation that impede the consistency and accuracy of high throughput sub-
stance screening. Additionally PHH tend to maintain short-term functionality in vitro
hence, failing to meet the requirements for long-term culture periods [134].
To overcome such problems immortalized cell lines from liver carcinoma have been
used. Human hepatocellular carcinoma cell-line (HepG2) is a widely used liver cell-line
for in vitro studies. Ease of culture and possession of hepatocyte-like functionality features
such as secreting liver-specific proteins has made HepG2 an alternative human-based cell
line for toxicity studies and compound screening. However, HepG2 are known to have
a low metabolic activity compared to PHH [135] and can poorly predict DILI, although
they show responses to drug treatment and express cytochrome 450 (CYP 450) [136].
Another more recent model cell-line derived from human liver hepatoma is the Hep-
aRG. HepaRG cells compared to HepG2 express higher liver-specific functions including
major phase I and phase II liver enzymes [137]. HepaRG therefore, are considered a closer
model to PHH and have found extensive use in metabolic and toxicology studies. The
cells have the ability to proliferate and differentiate when they are seeded in lower den-
sities (2.6 × 104 cells cm−2) [137] and generate two distinct sub-populations. More than
50% of the sub-populations are hepatocyte-like cells with one or two nuclei and express
liver biomarkers. The other sub-population has the phenotypic resemblance to endothelial
cells with an elongated distinct cytoplasm. HepaRG have also been shown to demonstrate
higher sensitivity in DILI prediction studies compared to HepG2 [136].
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Since the discovery of iPSC technology by reprogramming adult fibroblasts to a stem-
cell like state, first presented by Takahashi and Yamanaka [138], growing interest has led
to further development of several differentiation protocols for multiple cell types. This
approach has offered numerous advantages over the conventional in vitro models. For ex-
ample hiPSC-derived hepatocyte-like cells have been shown to express major functions of
the PHH, higher levels of enzyme production compared to cell-lines, and higher life span
compared to PHH [139]. hiPSC-derived hepatocytes provide an unlimited source of high
quality cells while eliminating the lot-to-lot variations associated with PHH. Additionally,
developing mature hepatocyte-like cells from different donors extends the possibility for
high-throughput and high-content screening studies. Figure 4.2 shows the brightfield mi-
croscope image of PHH (A), HepG2 (B) and hiPSC-hepatocytes (C) cultured in 2D flasks
under designated growth protocols.
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Figure 4.2: Brightfield microscope image of liver cell lines. The monolayer
culture of primary human hepatocytes (Cells provided by Bioreclamation-
IVT) (A), HepG2 (Sigma Aldrich, Germany) (B) and human induced pluripo-
tent stem cell (hiPSC)-derived hepatocytes (Cellular Dynamics International,
USA) (C). Scale = 50 µm.
Chapter 5
Methodology and experimental
procedure
T his chapter explains the flow simulations, operation principles of the microfluidic de-vices, optical tweezers set up, required materials and the equipment to design and
conduct the experimental work reported in papers I-IV. Cell culture and maintenance
protocols have been described according to the experimental conditions. To operate the
microfluidic devices, a number of steps were followed including sterilization of the mi-
crofluidic devices, preparation of the cells, setting up the fluid delivery tubing, pumps,
imaging equipment and the automation software.
Flow rates were programmed accordingly for each experiment and time-lapse imaging
was controlled by OpenLab software (PerkinElmer, Waltham, MA, USA). Assays, includ-
ing enzyme-linked immunosorbent assay (ELISA) and urea detection assay were conducted
according to the manufacturers’ protocols.
5.1 Finite element COMSOL simulations in mi-
crofluidic devices
5.1.1 4-inlet microfluidic chamber
For rapid environmental perturbations we used a 4-inlet microfluidic system. In the nu-
merical simulations the height of the device was set to 27 µm. As seen in figure 5.1 the
cell array with the desired number of cells was placed in the second junction of the 4-inlet
system. The coordinates for the array position were fed to the automation software. To
predict the behavior of the laminar flow in the chamber, flow velocity and diffusion of
substances were simulated jointly in the finite element software COMSOL multiphysics
(COMSOL Inc., Burlington, MA, USA). The position of the cell array and the exposure
area in the devices were decided based on the simulations. This step was imperative for
accurate and uniform cell exposure to the intended concentrations and to minimize the
diffusion-based mixing in the cell area. For all simulation conditions, incompressible, New-
tonian and laminar flow regime was selected. For all the channel walls a no-slip boundary
condition was chosen. The mesh elements in the simulations were selected as the default
tetrahedral settings. The inlets of the devices were set to the desired flow rates. The
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outlet pressure was set to 0 Pa. Constant fluid density and mass conservation under
Navier-Stokes equation (eq. 2.1) was applied. The ”laminar flow” module was selected
for the flow velocity simulations. The ”laminar flow” module takes into account all the
boundary conditions for the no-slip flow channels and calculates the flow velocity under
the stationary conditions (δu/δt=0) applied in eq. 2.1.
”Transport of diluted species” physics for diffusion studies, takes into account the
velocity field simulation output of the COMSOL study in the channels and calculates the
diffusion of chemicals with the assumption of the constant diffusion coefficient D. The
standard convection-diffusion equation (eq. 2.8) was used for the studies. Concentrations
of the chemicals were selected for the experimental conditions. Diffusion coefficients were
found from the literature.
As seen in figure 5.1 for Hog1 inhibitor (10 µM concentration) and sodium arsenite
(0.1 µM concentration) in the 4-inlet system, flow rates in the channels 1 to 4 were set
to 5, 5, 500, 5 nl min−1 for the inhibitor and 5, 5, 5, 1000 nl min−1 for sodium arsenite.
Diffusion coefficients were D = 2.4× 10−10 and D = 1.21× 10−9 m2 s−1 for the inhibitor
and sodium arsenite respectively. The cell array was fully covered by the substances under
these parameters verified by control experiments with fluorescein solution (not shown).
Figure 5.1: Diffusion of sodium arsenite and the Hog1 inhibitor in the mi-
crochannels were simulated under the flow rates of 5, 5, 500, 5 nl min−1 for
the inhibitor (A) and 5, 5, 5, 1000 nl min−1 (B) for sodium arsenite in inlets
1 to 4 respectively. The coordinates for positioning the cell array were found
from the numerical simulations primarily to ensure the full coverage of the
cells with the test compounds.
5.1.2 CellComb device for hydrodynamic cell trapping
To trap and immobilize yeast cells in a high throughput microfluidic device, a multi-trap
microfluidic system was designed and fabricated. Three parallel microfluidic channels were
connected via V-shaped pockets as described in papers II and III.
The flow velocity at the nuzzle junctions between the 2-µm openings and the side
channels reaches its maximum as depicted in figure 5.2. The height of the device has been
set to 5 µm in the simulations.
COMSOL boundary conditions mentioned in section 5.1.1 were applied. Figure
5.2 shows the velocity field for an example flow rate of 25 nl min−1. The flow
trajectories were added to the simulations by the streamline function to depict the
flow stream. The simulations have been carried out without introducing the cells to
the studies. The assumption was that cells of comparable diameter with the height
profile of the device will significantly block the traps and the high-flow region will
move along the device. This assumption was tested for by introducing spherical
obstacles to the geometry of the device. As seen in figure 5.2 the jet flow area is
transferred successively to the empty traps downstream the device. Same sets of
simulation studies were conducted for the device geometry tailored for mammalian
cell entrapment. The height profile of the device was changed to 15 µm, while the
other parameters were kept unchanged.
Figure 5.2: In the CellComb device, hydrodynamic cell entrapment was the
principle of operation. Cells were immobilized by the drag forces of the flow
and kept inside the microtraps for the successive substance exposure steps. In
the flow simulations in (A), (B) and (C) under the flow rate of 25 nl min−1,
spherical objects were positioned at the nib of the microtraps and the transi-
tion of the high-flow region alongside the device was followed. This principle
facilitated the cell loading step in the microfluidic devices.
5.1.3 Very large scale liver-lobule (VLSLL)-on-a-chip device
for 3D liver tissue formation
VLSLL-on-a-chip device aimed at creating a biomimetic structure to reproduce the
convective-diffusive blood circulation in the liver structure. The design of the device
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was inspired from the hexagonal classic liver lobule structures. Cell culture cham-
bers were in contact with the surrounding feed network through arrays of diffusion
passages with the cross section of 2 µm × 2 µm. The incorporated diffusion pas-
sages alongside the lobule-like chambers mimic the fenestrated LSECs, allowing for
the diffusion-based mass transport into the cell culture chambers and protect the
hepatocytes from shear force of the flow, which has previously been shown to have
a negative effect on cell viability and functionality [140].
In the simulation studies, the central vein mimetic in the center of each chamber
has been assigned to drain the fluids out of the culture chambers. As shown in
figure 5.3 the amount of shear rate and flow velocity drop significantly while moving
alongside the diffusion passages (from feed network towards the cell culture cham-
bers) and is minimized inside the cell culture chambers.
Based on the simulation results of the shear rate, γ (s−1), the shear stress for the
different regions of the device was calculated using
τ = γη. (5.1)
A significant decrease in the shear stress from τ = 0.04 dyne cm−1 in the sur-
rounding feed network to ≈ 0 in the culture chambers was obtained in the simula-
tions.
Simulation results showed that the role of convective flow inside the culture
chambers was insignificant and therefore the mass transport was dominated by dif-
fusion e.g. as seen in figure 5.3 for glucose with D = 9×10−10 m2 s−1. These results
were in agreement with the calculated Pe´clet number from eq. 2.9 as a measure of
convection and diffusion in the microchannels. From the calculations, Pe = 30 in
the feed network dropped to Pe = 1.8× 10−3 inside the culture chambers denoting
the diffusive transport in the cell culture area.
5.2 Experimental procedures for microfluidic de-
vice fabrication, operation and cell handling
5.2.1 Fabrication of microfluidic devices
Photolithography and soft polymer molding is one of the main fabrication techniques
in microfluidic devices, originally developed in semiconductor industry and silicon
electronics [76]. The feasibility of photolithography techniques in combination with
biocompatible materials such as PDMS has made them a widespread and robust
method of microfluidic fabrication. Compared to bulk and surface micromachining
approaches which involves wet or dry etching steps, lithography techniques provide
an easier and faster fabrication process without the need for expensive cleanroom
facilities and in-house micromachining tools. Photolithography involves a chromium
or transparency mask set with the desired patterns. The mask type is usually
decided depending on the required resolution and feature size. Transparency masks
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Figure 5.3: The simulation of the flow rates in the main feed network of a
single liver lobule chamber is shown with an inlet flow rate of 1 µl min−1 (A).
Flow velocity drops significantly inside the chambers compared to the feed
network. The shear rate has been shown in graph (B). Shear rate in region
A, the feed network, is the highest and in region D, inside the chambers is
negligible. Diffusion of glucose (D = 9× 10−10 m2 s−1) into the cell culture area
was simulated under the introduced velocity field (C).
provide a low-cost option for feature sizes typically with the critical dimensions
around 5-10 µm, whereas, chromium masks can achieve structures with sub-micron
resolutions [141].
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SU8 is a negative epoxy photoresist, which was initially developed in IBM labs
[142]. It has been used widely in microfluidic fabrication due to relatively easy
processing steps and the ability to produce high aspect ratio structures with a broad
thickness variety from hundreds of nanometers to hundreds of microns.
The SU8 resist is photosensitive in the i-line (λ=365 nm) region and after ul-
traviolet (UV) exposure through the photomask is developed and further processed
to yield the microfluidic masters. For complex or multilayer structure fabrication a
mask aligner is required to adjust and align the features on subsequent layers. How-
ever, single-layer microchannels can be easily fabricated using a basic broadband
UV lamp and plastic transparency masks.
In my work, I used silicon wafers as the substrate for constructing microfluidic
patterns. Typically, the fabrication process started with cleaning the silicon wafers
with a simple solvent-clean protocol. Wafers were immersed in acetone, methanol
and isopropyl alcohol (IPA) and dried with nitrogen pressure gun. The cleaning step
yielded a spotless surface for photoresist coating by removing dust, oil and organic
residues.
4-inlet microfluidic chamber
For fabrication of the systems we used 3-inch <100> double-side polished silicon
wafers as substrate. SU8-2015 (MicroChem Corp., Newton, MA, USA) was spin-
coated at 1500 rpm to create structures with the height feature of 27 µm. Wafers
underwent a soft bake step at 65◦C for 2 min and 95◦C for 5 minuets. After pho-
tolithography process using MA6 mask aligner (Suss MicroTec, Germany) wafers
were post exposure baked (PEB) at 65◦C and 95◦C for 3 and 10 min respectively.
Afterwards wafers were developed in mr-Dev 600 (microchem, Germany) and rinsed
with IPA. The finished wafers were used as SU8 masters for fabrication of devices
in PDMS.
Figure 5.4 illustrates the photolithography and PDMS molding steps to fabricate
the 4-inlet device.
The design of the 4-inlet system was slightly modified by adding alignment marks
and inlet-outlet nodes to the original design to fit a brass frame and punching nee-
dles as shown in figure 5.5(A). A brass ring was then fitted on the wafer using the
alignment marks. The lid for the ring carried the punching needles and a central
opening to cast PDMS on the wafers (figure 5.5(B) and (C)).
To make the devices, I prepared the PDMS mixture with a ratio of 10:1 PDMS:crosslinker
(papers I, II and III). After preparing the PDMS mixture and degassing in a
vacuum desiccator (Item Z119016, Sigma-Aldrich, Germany) for around 30 min, the
mixture was casted on silicon masters and cured in a conventional oven at 90◦C for
2-6 hours. PDMS replicas were then peeled off, rinsed with IPA and ethanol and
permanently bonded on microscope glass slides (Menzel #1 , VWR, SWEDEN) by
air plasma treatment (PDC-32G/32G-2 (115/230V), Harrick Plasma, Ithaca, NY,
USA) for 30 seconds.
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Figure 5.4: To fabricate a single-layer SU8 master with the height of 27 µm,
the photoresist was spin-coated (B) on the silicon wafers (A) at 1500 rpm.
After UV exposure (C) and developing step in mr-Dev 600 developer (D), SU8
masters were casted with PDMS (E). The crosslinked polymer was peeled off
the wafers and permanently bonded on the glass slides by air plasma surface
treatment (F).
CellComb device
To fabricate the CellComb device SU8-5 was spin-coated at the speed of 3000 rpm
for 30 seconds on 3-inch <100> silicon wafers and processed accordingly. Soft bake
times were similar to the 4-inlet device, however, PEB periods were adjusted to
1 and 3 min at 65◦C and 95◦C respectively. This fabrication protocol resulted in
microchannels with the height profile of 5 µm and minimum feature size of 2 µm
at the V-pockets. Similar steps were followed with SU8-25 for the mammalian cell
device with the height adjusted to 15 µm.
Figure 5.6 shows an illustration of the photolithography and PDMS molding steps
to fabricate the CellComb device. Fabrication of the microfluidic PDMS replicas
followed the same steps as explained for the 4-inlet device.
VLSLL device
Fabrication of VLSLL device followed a multilayer coat-bake protocol. Cell culture
layer and seed-feed network were fabricated in separate steps. To create the cell
culture layer, the first step was to fabricate the diffusion passages. SU8-2002 was
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Figure 5.5: A brass ring (A) was custom-made and aligned on the masters
to carry the PDMS lid and punching needles (B). After PDMS casting and
bonding (C-E), microfluidic devices were ready for attaching the syringes and
tubing (F).
spin-coated on 4-inch <100> wafers as shown in figure 5.7(A). After the lithography
process wafers were developed and hard baked at 160◦C for 10 min. Subsequently,
the processed wafer was coated with SU8-2035 to create the 60-µm media circulation
channels and honeycomb cell culture chambers (figure 5.7(B)). After UV exposure
and PEB steps the wafer was stored at room temperature for at least 24 hours for
rehydration without going through the development step. At the next step wafers
were coated multiple times with SU8-2035 to yield a 400-µm thick stencil layer to
readily pierce the central apertures in the PDMS cell culture chambers. To facilitate
the chemical and mechanical stability of the multilayer coating, a soft bake step of
10 min at 65◦C and 25 min at 95◦C was performed in between each coating. After
the last coating step wafers were UV exposed and left for 24 hours. All layers were
eventually developed in a single step. The top layer containing the seed-feed network
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Figure 5.6: Fabrication of CellComb device was similar to the 4-inlet mi-
crofluidics. The height of the device was adjusted for the average diameter
of a yeast cell (5 µm) and the critical dimension of 2 µm. Hence SU8-5 was
used for the SU8 master fabrication. The photolithography steps and PDMS
channel bonding are shown in (A-F)
was fabricated in a single photolithography step, see figure (5.8).
To prepare PDMS replicas of the VLSLL devices, PDMS for the thin layer,
containing the cell culture chambers and bottom fluidic network, was mixed in a
ratio of 5:1 and spin-coated at 200 rpm for 45 seconds on the silicon wafers as
seen in figure 5.7(J). To fabricate the top seed-feed network silicon masters were
casted with a PDMS mixture of 15:1 ratio. This combination facilitated a strong
PDMS-PDMS bonding between the two layers [143] and prevented leakage during
long-term cell experiments. Final devices (figure 5.8(G)) were rinsed with ethanol
after bonding and dried in the oven overnight. A sterilization with oxygen plasma
(BenchTop RIE (O2), Plasma-Therm, USA) was carried out at 100 W for 5-7 min.
Devices were then vacuum sealed and stored at room temperature.
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Figure 5.7: The VLSLL device comprised two layers of PDMS bonded on top
of each other. The cell culture chambers were incorporated in the thin bottom
layer while a separate seed feed network was fabricated. The SU8 master for
the thin layer was fabricated in a multi-coat approach and the features were
developed simultaneously. The fabrication steps for the cell culture chambers
are shown in (A-K).
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Figure 5.8: The SU8 master for the top layer was fabricated separately. The
single-layer fabrication steps were followed (A-F) and the height of the device
was adjusted to 100 µm. The top layer was eventually bonded by air plasma
on the thin bottom layer (G).
5.2.2 Integration of optical tweezers with epi-fluorescence
microscopy
In our studies we used an optical tweezers set up (see figure 5.9) as described in
the previous published work [81, 82, 144]. A single infrared 1070 nm laser beam
was focused through a 100× oil immersion objective (Leica Microsystems) with
NA=1.3. The output power of the laser was set to 400 mW on the laser control box
which attenuated in the optical pass and measured as 240 mW on the sample plane.
Trapping time for each cell was kept under 10 seconds previously optimized [145] to
maintain cell viability and minimize the photodamage to the cells.
Epi-fluorescence microscope stage (DMI 6000B, Leica Microsystems, Wetzlar,
Germany) was used to acquire all the fluorescent time-lapse images. The stage was
equipped with a broadband halogen lamp (Leica Microsystems, Wetzlar, Germany)
that was set to minimum output power (10 µW ) to prevent photobleaching of the
dyes and provided the excitation light for green, red and blue fulorophores. Confocal
microscopy was carried out in the microscope stage (LSM 700, Zeiss, Germany) at
CCI facilities, University of Gothenburg.
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Figure 5.9: This figure (A) shows the drawing of integration of the infrared
(1070 nm) laser (1) with the epi-fluorescence microscope stage. The laser light
passes through a manually controlled shutter (2). The gimbal mounted mirror
(GMM) (3) in a 90◦ angle guides the laser to the beam expansion telescope
(4). Through a dichroic mirror (5) the laser passes through a high NA = 1.3
objective (6) and gets focused on the sample plane (7). For brightfield imaging
sample is illuminated by the microscope lamp (8) through the condenser (9).
To acquire fluorescent images of the cells as described in chapter 3 (figure 3.2),
the sample is illuminated by a halogen lamp (10) and through the optical path
(11-12) the sample emission signal is collected and detected in the EMCCD
camera (13). Syringes and the tubing is connected to the microfluidic device
for sample handling (14). The components of the setup are marked in the
picture of the optical table (B) with corresponding numbering labels. (C)
shows the 4-inlet microfluidic chamber and immobilized yeast cells.
5.2.3 Cell preparation
Saccharomyces cerevisiae (yeast cell)
Yeast cell strain HSP104-GFP (BY4741 HSP104-GFP-HIS3-MX6) (Invitrogen) was
used to run the experiments in this thesis. Cells were cultured at 30◦C on a cell
shaker (220 rpm) in synthetic complete (SC) medium, 0.67% yeast nitrogen base
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(YNB) and 2% glucose supplemented with auxotrophic requirements. Prior to the
experiments cell density was measured by a spectrophotometer (biochrom, Cam-
bridge, England) and cells were collected at optical density (OD600)= 0.5-1.0.
NIH/3T3
NIH/3T3 mouse embryonic fibroblast cells were cultured in DMEM high glucose,
4mM L-glutamine cell culture medium (Gibco, ThermoFisher Scientific), 10% (bovine
calf serum) BCS (ThermoFisher Scientific) and 1% (penicyline-streptomycin) PEST
(ThermoFisher Scientific). Cells were cultured in 75 cm2 flasks (Sarstedt, Germany)
for 3-4 days to 60-80% confluency. Afterwards cells were passaged and prepared for
the experiments by trypsin/EDTA (GE healthcare) treatment.
HepG2
HepG2 cells were purchased from Sigma Aldrich, Germany. Cryopreserved vials were
thawed in 37◦C water bath for 2 min prior to the experiments. Afterwards cells were
transferred to pre-warmed RPMI 1640 (1X) GLUTAMAX
TM
cell culture medium
(Gibco, ThermoFisher Scientific), 10% (fetal bovine serum) FBS (Hyclone Thermo
Scientific), 1% PEST (Hyclone, Thermo Scientific) and cultured in a cell incubator
at 37◦C with 5% CO2. Cells were cultured in 75 cm2 flasks (Sarstedt, Germany)
for 4 days to 80% confluency. At this stage cells were detached from the culture
flasks using trypsin/EDTA, centrifuged at 200×g for 3 min and re-suspended in pre-
warmed media. Desired numbers of cells (3-7×105) were seeded in the devices mixed
with or without 20% mix of media/Geltrex R©(ThermoFisher scientific) in a 1:1 ratio.
hiPSC-derived hepatocytes
Cryopreserved vials of hiPSC-derived hepatocytes were purchased from Cellular Dy-
namics International (CDI, USA). iCell hepatocytes 2.0 were thawed in 37◦C water
bath for 3 min prior to the experiments. The plating and maintenance media were
prepared according to the manufacturer’s protocol. 1.5 ml B27 supplement 50X
(ThermoFisher Scientific), 20 ng ml−1 Oncostatin M (R&D Systems, Minneapolis,
USA), 0.1 µM Dexamethasone (ThermoFisher Scientific), 25 µg ml−1 Gentamicin
(ThermoFisher Scientific) and 1.5 ml iCell Hepatocytes 2.0 medium supplement
(CDI) were added to RPMI 1640 (1X) GLUTAMAX
TM
(Gibco, ThermoFisher Sci-
entific) to prepare the plating medium. The thawed cell vial was transferred to 10
ml of pre-warmed plating medium. After a centrifuge step at 200×g for 3 min, cells
were re-suspended and were ready to seed. Based on the protocol, 96 well plates
(NUNC
TM
) were coated with collagen I (Sigma Aldrich, Germany) in advance and
seeded with a cell density of 3×105 cells cm−2. Based on the experimental proce-
dure, devices were either pre-coated with collagen I or cells were mixed with 20%
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media/Geltrex
TM
in a 1:1 ratio. After cell seeding, plates and devices were trans-
ferred to the incubator and a complete media change step was performed 4 hours
later. Plating media was replaced on a daily basis until day 5. From day 5 plating
media was replaced with maintenance media (plating media without Oncostatin M)
and changed every other day.
5.2.4 Cell seeding and microfluidic device operation
4-inlet microfluidic chamber
To immobilize yeast cells in the 4-inlet devices, channels were treated with 1 mg
ml−1 concanavalin A (ConA), 100 mM NaCl and 10 mM Tris/HCl for 30 min prior
to the experiments. ConA solution was injected into all the channels and the device
was gently flushed with the solution. Systems were rinsed with YNB afterwards and
cell suspension as well as YNB, Hog1 inhibitor and sodium arsenite solutions were
connected to the designated inlets (paper I). Syringe pumps (CMA 400, CMA Mi-
crodialysis, Solna, Sweden) were programmed to deliver the desired flow rates and
controlled through a costume made automation in OpenLab software. Cells were
flushed into the chamber, captured by the optical trap and pushed against the bot-
tom of ConA-coated coverglass. ConA treatment enabled cell attachment on the
bottom of the coverglass. The size of the cell array was determined in the software
(5×5 cells). After cell-trapping step, cells were covered with the inhibitor or stress
solution based on the experimental plan (paper I).
CellComb device
Cell capturing in the CellComb device was performed in a single step of constant
flushing the cell inlet with the cell suspension (papers II and III). Cell loading
step required less than a minute to accomplish which was a major advantage over
the optical trapping technique. Single or multiple cells could be trapped inside the
V-pockets controlled by the geometry of the system and cell density. The main
channel of the device was rinsed with YNB after the cell-trapping step to flush out
the non-trapped cells. Stress solutions were introduced to the system via the main
or side inlets and imaging was performed. The device could be imaged in multiple
sections (13 sections along the length of the device with 8 pockets in each section,
fitted to the field of view of the camera) by moving the microscope stage.
The first step in operation of the CellComb with NIH/3T3 cells was aimed at suc-
cessfully immobilizing the cells in the device. To achieve the single cell trapping,
cells were detached from the culture flasks and resuspended in fresh cell medium
after a centrifugation step. In paper II we explored the possibility of trapping cells
in suspension with the same principle described for yeast cells. Although the cell
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entrapment step was successfully conducted, further care was required to maintain
the cells viable and functional.
VLSLL device
VLSLL device was tailored to facilitate long-term culture of human liver cells (paper
IV). To start each experiment sterilized devices were placed in a vacuum desiccator
at least 24 hours prior to cell seeding. This step aided the cell loading as air-liquid
displacement inside the PDMS body provided a temporary suction effect inside
the device. A negative pressure of 3 psi applied to the feeding inlet helped load
the cells uniformly and achieve a packed population inside the culture chambers.
Cell preparation as described in section 5.2.3 was performed accordingly based on
the plating and maintenance protocols for HepG2 and hiPSC-derived hepatocytes.
Special care was necessary in the cell seeding process to impose the least stress
and damage to the cells. The hiPSC-derived hepatocytes were the most fragile
after thawing and plating process was carried out as suggested by the provider
(CDI). After cell seeding step devices were left in a no-flow condition to aid the
cell adherence and stabilize the cultures. Cell culture media was connected to the
feed inlets via microfluidic connectors and syringe pumps were programmed to 1 µl
min−1 flow rates (paper IV). Devices were inspected for cell morphology and flow
conditions with a light microscope (Olympus, CKX41, Japan).
5.2.5 Assay, buffer, and substance preparation
Hog1 inhibitor
We dissolved Hog1 inhibitor 4-(1-benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)-N-isopropylpyridin-
2-amine (M = 478.67 g mol−1) in dimethylsulfoxide (DMSO) [146]. The concentra-
tion of stock solution was 1.9 mM and diluted in YNB on the day of experiments to
the final concentration of 10 µM.
Sodium arsenite (NaAsO2)
Sodium arsenite (NaAsO2) (Sigma Aldrich, Germany) was fresh prepared on the day
of experiment (dissolved in Mili-Q water) and brought to the final concentrations of
0.1, and 0.5 mM (paper I) and 0.5 mM (paper III).
Fluorescein solution
Uranine (disodium salt form) was dissolved in Mili-Q water and a final concentration
of 0.2 mM fluorescein (green fluorescent dye) solution was prepared (paper II).
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ELISA
Human albumin ELISA kit (Bethyl laboratories, Montgomery, TX) was used to mea-
sure the albumin secreted by hepatocytes both in the devices and 96 wells. Based on
the manufacturer’s protocol clear 96 wells (NUNC
TM
) were coated with the coating
antibody mixed in coating buffer. Wells were then washed, and blocking solution
was added. After sample dilution in the sample-conjugate buffer and incubation
at room temperature, detection antibody was added to the wells. Ready-to-use
TMB solution was added to each well to create the luminescence. The reaction was
stopped by adding the stop solution and wells were measured in a microtiter plate
reader (FLUOstar Omega, BMG LABTECH, Germany) at 450 nm wavelength in
absorbance mode.
Urea assay
Urea synthesis by hepatocytes was measured by an enzyme reaction urea assay kit
(Sigma Aldrich, Germany). Samples were diluted in urea assay buffer, and added
to 96 wells (NUNC
TM
). The reaction mix including the enzyme mix, the developer,
the converting enzyme and the peroxidase solution was prepared according to the
manufacturer’s protocol. After carefully adding the reaction mix to the samples,
plates were incubated at 37◦C for 60 min and measured at 570 nm in absorbance
mode.
Cell viability Live/Dead R© kit
Mammalian cell viability kit was purchased from ThermoFisher Scientific. Calcein
AM was used to detect viable cells based on the esterase activity of the cells. Live
cells cleave the calcein AM dye by the intercellular esterases and turn it to a green
fluorescent probe. Ethedium homodimer-1 (Ethd-1) is a red fluorescent dye that
passes through the damaged cell membranes and binds to the DNA of apoptotic
or necrotic cells. Calcein AM and ethidium homodimer-1 (Ethd-1) were prepared
fresh in PBS (-Ca, -Mg) to the final concentrations of 4-6 µM before every staining.
96 wells and microfluidic devices were washed prior to the staining with PBS. Cells
were incubated with the dyes at 37◦C for periods between 30-90 min (paper IV).
After another wash step cells were imaged using the epi-fluorescence or confocal
microscope stage.
Hoechst dye for cell nuclei staining
Hoechst 33342 fluorescent stain (20 mM, item 62249) was purchased from Ther-
moFisher Scientific. Hoechst is a blue florescent dye that binds to DNA with high
affinity and without interacting with the nucleic acids. The dye is highly cell per-
meable and is commonly used to stain the nuclei of eukaryotic cells. Upon exposure
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it provides a distinct blue fluorescence signal at 460 - 490 nm. The fluorescent dye
was prepared fresh before each staining and was diluted to the final concentration
of 10 µg ml−1 in PBS (-Ca, -Mg). Incubation time was between 10-30 min.
CDFDA for bile canaliculi staining
CDFDA (5-and-6)-carboxy-2’,7’,-dichlorofluorescein diacetate (Sigma Aldrich, Ger-
many) was used to stain the hepatocytes for formation of bile canaliculi network.
By means of intercellular esterase activity, hepatocytes cleave CDFDA dye. Upon
staining, the cleaved dye loses the diacetate part and is then transported out of the
cytoplasm into the canaliculi network in between the adjacent cells with involvement
of MRP2 transporters [123]. Final concentration of 10 µM was prepared fresh before
each staining and incubation time set to 10-15 min at 37◦C.
5.3 Data analysis
To analyze the results obtained from the experiments in papers I-IV, the data was
processed in image analysis softwares for the brightfield and fluorescence microscopy
images. For yeast cells the imaging data was analyzed to quantify the number of
Hsp104-GFP aggregates under different experimental scenarios. For experiments
with the liver cells, live cell staining fluorescent data was obtained and used to
assess cell integrity and formation of multi-layer cell structures in the microfluidic
devices.
Image analysis
In papers I, II and III the acquisition of the data was handled by Openlab
software. Time-lapse images of the cells in brightfield and fluorescence mode were
taken in series of stacks along the z axis for each time point and every field of view.
The separation between the stacks was decided based on control experiments and
trial runs. Typically we acquired 7-10 images for yeast cells with the z-slice spac-
ing between 0.6-0.9 µm. The fluorescent data from each image series was overlaid
with the brightfield images and analyzed in a custom-made image analysis soft-
ware, CellStress [147]. To identify the outline of the cells, the algorithm for cell
contour recognition in the software CellStat [148] was used jointly with CellStress.
The fluorescent data was analyzed based on the intensity of the signal from each
z-slice and the intensity points found in the layer. This way we could automati-
cally obtain the number of total aggregates in each cell. The results of the analysis
round were manually controlled to avoid false aggregate count. To analyze the
fluorescence microscopy data acquired from staining of liver cells, software ImageJ
(https://imagej.nih.gov/ij/) was used extensively to separate color channels and
overlay stained layers with calcein AM, hoechst 33342, Ethd-1 and CDFDA.
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Plate-based assay data analysis
To analyze the ELISA and urea assay measurements in paper IV, a series of sample
dilutions were performed to maintain the read out of the sample absorbance in the
linear range of the standard curves of the assays.
ELISA analysis
The ELISA kit was optimized to detect human albumin in the serum with a stan-
dard curve obtained for a dilution series of 6.25 - 400 ng ml−1. In each absorbance
measurement run with sample and standard duplicates, results were monitored for
the duplicates to be within a 10% range from each other. Each assay was repeated
at least 2 to 4 times to ensure the consistency of the results. The standard curve
for each measurement was prepared by subtracting the blank values from the av-
erage of duplicate standard concentrations. The new values were plotted against
the corresponding albumin concentrations from the assay. The standard curve was
obtained by applying a 4 parameter logistic regression curve-fitting. The concentra-
tion of unknown samples were found by correlating the average absorbance values
to the standard concentrations. The sample dilution factors were applied to obtain
corrected albumin values. The results were then corrected for the number of seeded
cells in each device or 96 well and the period of time the cell supernatant was col-
lected. Final results were presented as the amount of albumin in ng/h/106 cells as
seen in figure 6.6(A) and figure 6.7(A).
Urea analysis
Urea assay is an enzyme reaction assay that results in a final reaction product
which, through colorimetric absorbance measurement is correlated to the amount
of urea synthesized by the hepatocytes. All the precautions taken with the ELISA
measurements were repeated in terms of assay repetition and data consistency with
the urea samples. The steps in preparation of the standard curve were the same and
only the fitting algorithm was changed to the linear least square regression model.
Results of measurements were corrected for the dilution factors, cell numbers and
period of the supernatant collection shown in ng/h/106 cells as seen in figure 6.6(B)
and figure 6.7(B).
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Chapter 6
Summary of results
T his chapter summarizes the experimental results in the appended papers.
6.1 Paper I: Microfluidic chamber in combina-
tion with optical tweezers to study uptake of
sodium arsenite in single yeast cells
In paper I, we took advantage of an integrated experimental set up including an epi-
fluorescence microscope and a single beam (λ = 1070 nm) infrared optical tweezers
setup. In this study we conducted the induction and regulation of uptake of sodium
arsenite in yeast in presence of glucose, mediated by a Hog1 inhibitor. We used
GFP-tagged Hsp104 as the readout for arsenite uptake by the cells.
Various concentrations (5-25 µM) and incubation times (5-45 min) of the Hog1
inhibitor were introduced to the cell environment to eliminate the risk of false ag-
gregate formation readouts induced by the inhibitor.
The final concentration of 10 µM and pre-incubation time of 5 min were selected
for the inhibitor.
Compared to the control experiments with only YNB, exposing cells to 0.1 mM
and 0.5 mM solutions of arsenite resulted in time- and concentration dependent
increase in the formation of Hsp104-GFP protein foci, which, was attributed to the
increase in concentration of arsenite in the cytosol. After 40 min of continuous
arsenite exposure, around 50 % of the cells showed 2-4 aggregates per cell.
In the next step we pre-incubated the cell arrays with the Hog1 inhibitor for 5
min and introduced 0.1 mM arsenite solution into the chamber for an additional 45
min time period.
Our results as shown in figure 6.1 clearly showed that both the maximum num-
ber of aggregates per cell (nine aggregates) as well as the proportion of cells with
aggregates (80 %) increased compared to the arsenite-only scenario.
Figure 6.1(A) shows the cells at the final time point of the experiments (45 min)
for As (III)-only treatment whereas figure 6.1(B) shows the cells treated with 10
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µM of Hog1 inhibitor for 5 min prior to arsenite exposure. As seen in figure 6.1(C)
and (D) the number of aggregates in total and per cell, as well as the proportion of
the cells showing aggregates indicate a significant increase with inhibitor treatment.
This can also be seen in the number of the aggregates formed after 45 min under
the two experimental conditions in the box plot in figure 6.1(E). The significance
between the two data sets found using one-way ANOVA test (∗ = p < 0.05).
The mechanism behind the significant role of the Hog1 inhibitor in increasing the
uptake of As (III) and hence damaged protein sites can possibly be explained with a
hypothesis where the kinase activity of Hog1 is disabled in presence of the inhibitor
compound. When cells are exposed to As (III) without the inhibitor treatment,
phosphorylation of Hog1 via down-regulation of Fps1, through phosphorylation of
Fps1, leads to drop in the uptake of arsenite. However, treatment with the Hog1
inhibitor, as seen in figure 6.2 results in the impairment of down-regulation of Fps1
by Hog1 and therefore increase in the uptake of As (III) via Fps1. Based on this
model we could explain the increase in the number of protein foci with Hog1 inhibitor
pre-incubation.
Additionally, we observed an earlier aggregate appearance in Hog1 inhibitor and
arsenite co-administered cells. Benefiting from the single-cell analysis approach we
analyzed the response of mother and daughter cells (buds), that were attached to
the mother cells at the time of experiments. The cell-cell heterogeneity from varying
cell cycles among the mature cells and the buds confirmed a distinct pattern in our
data. Our results depicted in a box plot with the average number of aggregates at
45 min, in figure 6.3 showed that mother cells accumulated more protein damaged
sites compared to the young buds during the course of treatment with both inhibitor
and arsenite. Whereas, in the arsenite-only scenario no significant differences were
observed between the mothers and fresh buds.
6.2 Paper II: Design and fabrication of a high-
throughput microfluidic device for single-cell
capture, exposure and imaging
In paper II I designed and fabricated a high-throughput multi-inlet microfluidic
device for hydrodynamic trapping of single cells inside the V-shaped traps. This
paper addresses the need for application-specific and high-precision tools to collect
data for statistical analysis. We demonstrated that with an easy-to-operate mi-
crofluidic device (CellComb) it is possible to immobilize individual or groups of cells
in PDMS blocks arranged in V-shaped placement. Via formation of high-velocity
nodes at the nibs of the traps cells were dragged into the pockets and maintained
with the stream of the flow. COMSOL simulations confirmed the formation of high
jet flows exiting the traps into the two wider adjacent channels. Due to the increase
of the flow resistance in the filled pockets, the high velocity region of the device
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moved along the microchannels. Cell trapping procedure was performed using a
syringe pump. The device could be effectively loaded with fast flushing the pump
for 30-60 s. The device was designed to allow for cellular microenvironment pertur-
bations with various substances. Full coverage of the cells in the main channel as
well as local exposure from the side channels was shown. Trapping individual yeast
cells and NIH/3T3 embryonic mouse fibroblast cells were achieved with tailoring
the geometry of the device to the average size of each cell type (around 13-15 µm
for NIT/3T3 cells measured on acquired microscope images). The single-block Cell-
Comb device could accommodate up to 6 yeast cells in each trap and total number
of 624 cells in a completely filled device while maintaining the single-cell possibil-
ities. The capability of the device in administration of extracellular perturbations
was demonstrated with 0.2 mM fluorescein solution. We also demonstrated that the
device could be operated in a comparatively low flow rate regime (nl min−1) with
stable cell immobilization and exposure.
6.3 Paper III: Effect of flow rate variation on for-
mation of Hsp104 foci in yeast cells using the
CellComb device
In paper III we used the principle developed in paper II for hydrodynamic cap-
turing of yeast cells. The effect of flow rate dependency of Hsp104-GFP protein
aggregate formation in single yeast cells was studied. Cells were diluted to the
OD600= 0.1-0.3 and seeded in the devices. We could achieve up to 80% trapping
efficiency with multiple cells in each trap. Single-cell trapping efficiency of 60% was
achieved for single-cell occupancy in each pocket. Controlling the initial cell density
and preparing multiple dilutions was the only effort required to ensure a uniform
cell loading without accumulating the microchannels with uncontrolled number of
cells. Sodium arsenite was prepared at the final concentration of 0.5 mM to assure
redistribution of Hsp104-GFP as confirmed in paper I. We observed a distinct het-
erogeneity in cellular responses under low (25 nl min−1), moderate (50 nl min−1)
and high (100 nl min−1) flow rates. Our data as seen in figure 6.4 showed a trend in
formation of larger number of aggregates under the low flow rate compared to the
high flow rate settings. We also observed the early appearance (15-20 min from the
start of arsenite treatment) of Hsp104-GFP aggregates under 25 nl min−1 flow rate.
Figure 6.5 shows the average number of aggregates per section of the device at 45
min under different As (III) flow rates compared to the non-treated (NT) cells. We
attributed this increase in the uptake of the substance to the higher availability of
the chemical in the cell proximity under low flow rates, leading to increased passive
diffusion of As (III).
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6.4 Paper IV: Long-term maintenance of HepG2
and hiPSC-derived hepatocytes in the VLSLL-
on-a-chip device
In paper IV, a liver-on-a-chip device developed for drug metabolism studies in
long-term in vitro cultures of liver cells was designed and evaluated. (VLSLL)-on-
a-chip microfluidic device facilitated 3D tissue formation, long-term cultivation and
monitoring of human hepatocytes. The two-layer culture and feed network configu-
ration allowed for a compact and integrated device which, primarily was designed to
be incorporate in modular multi-organ human-on-a-chip platforms. A single device
comprised 18 hexagonal cell culture chambers mimicking the geometrical dimensions
of the classic liver lobule. The diameter of the chambers varied between 1.2 - 2.4
mm.
In my experiments, devices were validated with HepG2 and hiPSC-derived hep-
atocytes. We operated the devices under two sets of experimental conditions for cell
culturing.
The first set, were the experiments where I seeded the cells into the culture
chambers without addition of ECM. Although this approach worked to a certain
extent with the HepG2 cells, the hiPSC-hepatocytes demonstrated a limited adher-
ing capability to the surface of the device and eventually lost viability. HepG2 cells
on the other hand could be kept viable up to one week in culture with a significant
decline of albumin secretion and urea synthesis from day 4 (Supplementary figure
3, paper IV).
The second set of experiments included using various forms of ECM involvement
in the cell culture process. Devices were coated with rat tail-collagen I (Sigma
Aldrich, Germany) prior to the experiments, or cells were mixed at the time of
seeding with different concentrations of Geltrex R© (0.15 mg ml−1) or Geltrex
TM
(15
mg ml−1). The second set of experiments revealed that any form of ECM addition
to the culture system significantly improved the cell viability and resulted in longer
maintenance of the cultures. HepG2 cells showed stable levels of albumin and urea
for at least two weeks as seen in figure 6.6. hiPSC-hepatocytes could be maintained
in culture for at least three weeks with collagen I coating as well as Geltrex
TM
mixing.
Our results showed (see figure 6.7) that the levels of albumin in hiPSC-hepatocytes
were significantly higher than the HepG2.
Urea synthesis was, however, higher in HepG2 cells, yet comparable in case of
hiPSC-hepatocytes. As it has been published by Berger et al [149] levels of urea
synthesis and functionality measures can significantly vary based on the donor vari-
ation of hiPSC-hepatocytes. Additionally, the different formulation of the culture
media can contribute to different levels of urea synthesis. Another plausible argu-
ment could be cell proliferation in HepG2 after seeding and formation of 3D tumor
structures while, the maturation process of iPSC to hepatocytes impairs the pro-
liferation capability of hiPSC-hepatocytes. Therefore, proliferation of HepG2 cells
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may effect the urea synthesis. Further experiments are required to validate either of
these explanations possibly by using assays to monitor the proliferation of the cells.
To access the viability of HepG2 cells three molecular probes, calcein AM, Ethd-1
and hoechst were used. Figure 6.8 shows a confocal image of the HepG2 cells stained
with the three dyes on day 2 in culture. The viability of the HepG2 was constantly
monitored during the culture period (up to 14 days, paper IV, supplementary figure
2) and used in correspondence with the albumin and urea production as a measure
of cell integrity.
To verify the formation of bile canaliculi in the cultures, hiPSC-hepatocytes were
stained with CDFDA dye. We observed the formation of bile canaliculi networks
only in the 3D cultures (figure 6.9(A)). The formation of bile canaliculi network
in the interfaces of tissue-like structures was observed as shown in paper IV on
day 8 and day 16 in the cultures. Monolayer cultures of hepatocytes showed an
insignificant formation of bile canaliculi as seen in figure 6.9(B).
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Figure 6.1: As (III) and Hog1 inhibitor co-administration in our experiments
showed a significant increase in the arsenite uptake by the cells. (A) is the
fluorescent image of an array of yeast cells subjected to 0.1 mM of sodium
arsenite for 45 min. (B) shows the final time point of the experiment for the
inhibitor pre-treatment scenario (Scale = 10 µm). The number of Hsp104-GFP
aggregates in the arsenite-only scenario (C) significantly increased with the 5
min pre-incubation with the Hog1 inhibitor (D), shown for the percentage of
all cells in the experiment. The average number of aggregates in the three
scenarios of non-treated (NT), arsenite-only and inhibitor co-administration
has been shown in the box plot denoting the significance of inhibitor treatment
in Hsp104 redistribution. (*=p < 0.05)
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Figure 6.2: In our model for the uptake of As (III) we show that the port
of entry of arsenite to the cell is through Fps1 channels and in case of no co-
administration of the Hog1 inhibitor the compound gets transported out of the
cell through Acr3 export pumps or enters the glutathione cycle. In presence of
Hog1 inhibiter, the phosphorylation of Hog1 and therefore the activity of Fps1
gets impaired and concentration of arsenite increases in the cytosol resulting
in the early appearance and elevation of the Hsp104-GFP foci with distinct
fluorescent signal. Other possible scenarios such as involvement and activation
of other kinase pathways are likely in mediation of Hog1 inhibitor and increase
of the arsenite uptake by the cells, however, further experiments are required
to assess these possibilities.
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Figure 6.3: The number of aggregates in the cells is shown for the mother and
daughter cells at the final time point of the experiments 45 min. We observed
that mother cells accumulated significantly higher number of aggregates com-
pared to the buds in the co-administration of Hog1 inhibitor and As scenario.
This effect was not pronounced in the As-only treatment. Also we observed
that the uptake of arsenite showed a larger significance in only mother cells
under the two treatment scenarios. (*=p < 0.05)
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Figure 6.4: In the CellComb device, cells were subjected to three different
flow rate scenarios. The device was operated under relatively small flow rates
with the 100 nl min-1 marked as highest and 25 nl min-1 as the lowest flow
rate. Cells were immobilized in the traps prior to treatments (A). Our data
showed that number of aggregates increased with the decrease in the inlet flow
rates (C-E) compared to the NT cells (B) (Scale = 10 µm). Arrows show the
Hsp104 aggregates.
47
Figure 6.5: The box plot shows the significance of the flow rate reduction on
the Hsp104 relocalization. The average number of aggregates in each section of
the device (field of view of the camera with 8 trap placements) was compared
for different flow scenarios at final time point of 45 min. (*=p < 0.05).
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Figure 6.6: Secretion of protein albumin (A) and synthesis of urea (B) as
liver-specific metabolic markers was monitored in the HepG2 cultures in the
VLSLL device for 14 days. The cell suspension was seeded into the devices
in a 1:1 v/v mixture with 20% diluted Geltrex R© (0.15 mg ml−1). Cultures
showed sustained levels of albumin and urea production. Error bars show the
standard deviation.
Figure 6.7: hiPSC-hepatocytes were seeded into 96 wells and devices pre-
coated with collagen. The cell adhesion and viability was maintained on the
gel-treated surfaces and devices as well as 96 well plates were measured for
the amount of albumin and urea production. Both albumin secretion and
urea synthesis were higher in the VLSLL devices compared to the 96 well
plates under the time period of 21 days. (A) shows the comparison of albumin
secretion between devices and 96 wells whereas (B) depicts the differences in
urea synthesis. Error bars are the standard deviation.
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Figure 6.8: The confocal image of HepG2 cells in culture in the VLSLL device,
2 days after seeding. 30 stacks of images were taken with 2 µm split. Cells
were stained with calcein AM (green, live cells), Ethd-1(red, dead cells) and
hoechst (blue, cell nuclei). The images were taken in the center for cellular
imaging (CCI), University of Gothenburg. (Scale = 50 µm)
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Figure 6.9: Exertion of bile is the hepatocyte-specific role in the liver. In our
experiments we stained hiPSC-hepatocytes with CDFDA dye (green). The
exported fluorescent part (with cleaved diacetate part by the intercellular
esterase activity) of the stain is visualized with the green signal. In the 3D
cultures formation of canalicular network is evident (A) while in the monolayer
cultures cells show insignificant bile canaliculi formation (B). The cell nuclei
have been stained with hoechst (blue). Arrows show the exerted bile to the
canaliculi network. (Scale = 50 µm)
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Chapter 7
Conclusions and future work
T he work I have done in my thesis focuses on experimental validation of microflu-idic devices to test chemical and drug compounds on single-cells and tissue-like
microcultures. I constructed custom-made microfluidic devices with the ultimate
goal of creating in vitro physiologically relevant systems to study the cytotoxicity
effects of test drug compounds.
Single-cell extracellular perturbation studies were carried out in two different ex-
perimental approaches for time- and concentration dependent extracellular sodium
arsenite exposure effects. In approach one, discussed in paper I we explained how
the combination of optical tweezers and a 4-inlet microfluidic device was used to reg-
ulate the uptake of arsenite in single yeast cell. We showed that a 40-min-treatment
of 0.1 mM and 0.5 mM arsenite under constant flow rate of 1 µl min−1 induced
Hsp104-GFP aggregation formation in the cells with concentration-dependent ten-
dency. We observed a distinct heterogeneity in cellular responses to the treatment.
We further showed that without any genetic intervention and by applying a con-
trolled co-administration of a Hog1 inhibitor with a pre-incubation step of 5 min
and concentration of 10 µM, the percentage of cells showing aggregates was elevated
from 50 % to 80 %. Our data showed that the maximum number of aggregates per
cell increased by 50 %.
In papers II and III I broadened the approach used in paper I to a microfluidic
device that overcame the limitations of the previous experimental setting in cell and
fluid handling. In paper I the throughput of the studies was limited to one field
of view of the camera, a limited number of 25 cells in each run and impractical
to carry out with mammalian cells. The cell loading with optical tweezers was
tedious and rather complex. Specifically for a non-native user, operation of the
system was technically challenging. The possibility of photo-damaging the cells
by the focused laser light added another limitation to cell handling. I designed
and fabricated a microfluidic device, CellComb, with 104 individual microtraps. A
single device could be sequentially imaged in 13 sections along the x axis, with each
section incorporating 8 microtraps in the field of view of the camera. Cells could be
loaded in a simple step and the device increased the throughput of the experiments
significantly to up to 625 cells with full capacity of a single device. Using the
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CellComb device, I could induce flow-rate dependent Hsp104-GFP protein foci in
the trapped yeast cells. The results showed that cells were more susceptible to
arsenite toxicity in the low flow rate condition (25 nl min−1) and demonstrated a
larger degree of protein damage compared to the high flow rate condition (100 nl
min−1).
In this device I incorporated 2-µm-wide passages adjacent with two side chan-
nels. The flow of drug and nutrient molecules could be transported in and out of
the central channel and facilitated an additional degree of flexibility to control the
microfluidic environment. By injecting the compounds through the inlet of the cen-
tral channel cells could be exposed to the test compounds by convective flow while
local exposure of the trapped cells was feasible through the neighboring channels.
By increasing the flow rates in the side channels by 2-3 folds compared to the central
channel (e.g. 300 nl min−1 in the side channels - 150 nl min−1 in the central channel),
local exposure of the cells to fluorescein solution as a drug surrogate for visualization
purposes, was demonstrated in paper II. Additionally, NIH/3T3 were seeded into
the microfluidic devices. This was the first step in transforming the experimental
systems for conducting more complex experimental plans with mammalian cells in
our lab. This design principle served as inspiration and the motivation to promote
the diffusion-based mass transport cell culture chambers that were developed further
in paper IV to an organ-on-a-chip microfluidic device.
In paper IV the possibilities of the microfluidic devices developed previously
were expanded to an integrated platform with the ultimate goal of building the
compartments for an integrated human-based in vitro multi-organ system. I chose
to develop the device to mimic the geometrical as well as convection-diffusion mass
transport of a classic liver lobule. The cell culture chambers were arranged in a hon-
eycomb layout. Each honeycomb chamber had a diameter of 1.2-2.4 mm, mimicking
the geometrical constraints of a classic liver lobule. The diffusion-dominated cell
media circulation in the device conveyed nutrients to the culture chambers via 2-
µm-wide passages. The microscope imaging of the morphological changes alongside
cell staining with fluorescent dyes revealed the promotion of 3D tissue-like structure
formation in the device. HepG2 and hiPSC-derived hepatocytes were cultured in
the devices for periods of up to three weeks. Formation of bile canaliculi network
was observed in the hiPSC-derived hepatocytes on various days of culture (e.g. day
8 and day 16) while it was absent in the 2D monolayer cultures.
The intertwined nature of environmental arsenic pollution with human health
and the possibilities of therapeutic applications of the compound opens up an in-
teresting and critical research field to understand and control the mechanisms of
arsenite toxicity in cells. I believe that using microfluidic dynamic cellular envi-
ronment in combination with single-cell analysis to study arsenite cytotoxicity in
mammalian cells is imperative. The reproduction of the results with the homologue
proteins in mammalian and human cells will reveal interesting results. Up-scaling
the CellComb device in an integrated layout to enable screening of large numbers
of cells must be considered. With the diffusion-based mass transport system sub-
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stantially developed in the VLSLL device, single-cell studies on cell-cell interactions
and intercellular synchronization can be conducted with modified designs of the
CellComb device. Examples of such studies include the glycolytic oscillations and
synchronization in single yeast and beta-cells. These experiments are currently un-
der development in our research group.
The focus of the future work with VLSLL device must be on validating the
platform with high throughput testing of drugs. Investigating the capabilities of the
device in identifying cytotoxicity of established and unknown hepatotoxic drugs as
well as comparisons between the cultures of PHH and hiPSC-hepatocytes should be
performed.
Currently, I am evaluating the responses of long-term cultures of hiPSC-derived
hepatocytes to substrate and inducer drugs of CYP 3A4 and CYP 2C9 enzymes.
Dose-response studies with known hepatotoxic drugs such as diclofenac is also un-
der evaluation. Additionally, I am conducting experiments on co-culturing hiPSC-
derived hepatocytes with NPCs of the liver. These studies are expected to develop
the physiological aspect of the platform from a single cell type to an organotypic
niche and promote the interactions of different liver cells to represent a robust in
vitro model system.
Another interesting area of study will be the integration of VLSLL device with
other OOC platforms such as kidney and gut to create a relevant model for the com-
plete drug clearance circle. Studying DILI in presence of other organ compartments
such as heart or blood-brain barrier and the interplay of these compartments will
certainly be interesting. The combination of the VLSLL device with hiPSC-derived
disease models will open up another interesting line of research. The future of per-
sonalized medicine relies heavily on the development of in vitro screening systems
which not only are capable of conducting high throughput ADMET studies but are
also capable of representing patient-specific physiologically relevant characteristics.
Multi-organ, human-on-a-chip and patient-on-a-chip microphysiological platforms
will experience a vast development and revolutionize the process of drug discovery
as we know it today.
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